Us Renal Care Uptown Dialysis is a medicare approved dialysis facility center in Naples, Florida and it has 16 dialysis stations. It is located in Collier county at 2700 Imokalee Road, Naples, FL, 34110. You can reach out to the office of Us Renal Care Uptown Dialysis at (239) 596-3044. This dialysis clinic is managed and/or owned by Us Renal Care, Inc.. Us Renal Care Uptown Dialysis has the following ownership type - Profit. It was first certified by medicare in July, 2005. The medicare id for this facility is 102821 and it accepts patients under medicare ESRD program.
| Name | Us Renal Care Uptown Dialysis |
|---|---|
| Location | 2700 Imokalee Road, Naples, Florida |
| No. of Dialysis Stations | 16 |
| Medicare ID | 102821 |
| Managed By | Us Renal Care, Inc. |
| Ownership Type | Profit |
| Late Shifts | No |
| 2700 Imokalee Road, Naples, Florida, 34110 | |
| (239) 596-3044 | |
| Not Available |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.
The Center for Healthcare Research & Transformation (CHRT) based at the University of Michigan today released its Prematurity Issue Brief that shows pre-term births -- births at less than 37 weeks of gestation -- are the leading cause of health problems in infants and estimated to cost the U.S. more than $26 billion annually. In addition, the report shows that a black infant in Michigan is 70% more likely to be born prematurely than an infant of any other race.
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
Pancreatic cancer is predicted to become the second leading cause of cancer-related deaths by 2030. However, recent developments in staging and treatment provide options to improve the long-term survival rate for an otherwise devastating diagnosis.
› Verified 9 days ago
| NPI Number | 1376579607 |
| Doing Business As | Kidney Institute Of Naples, Llc |
| Address | 878 109th Ave N Naples, Florida, 34108 |
| Phone Number | (239) 596-3044 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.
The Center for Healthcare Research & Transformation (CHRT) based at the University of Michigan today released its Prematurity Issue Brief that shows pre-term births -- births at less than 37 weeks of gestation -- are the leading cause of health problems in infants and estimated to cost the U.S. more than $26 billion annually. In addition, the report shows that a black infant in Michigan is 70% more likely to be born prematurely than an infant of any other race.
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
Pancreatic cancer is predicted to become the second leading cause of cancer-related deaths by 2030. However, recent developments in staging and treatment provide options to improve the long-term survival rate for an otherwise devastating diagnosis.
› Verified 9 days ago
| NPI Number | 1770934762 |
| Organization Name | U.s. Renal Care Uptown Naples Dialysis |
| Doing Business As | Usrc Uptown Naples Llc |
| Address | 2700 Immokalee Rd Ste 22 Naples, Florida, 34110 |
| Phone Number | (239) 596-3044 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.
The Center for Healthcare Research & Transformation (CHRT) based at the University of Michigan today released its Prematurity Issue Brief that shows pre-term births -- births at less than 37 weeks of gestation -- are the leading cause of health problems in infants and estimated to cost the U.S. more than $26 billion annually. In addition, the report shows that a black infant in Michigan is 70% more likely to be born prematurely than an infant of any other race.
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
Pancreatic cancer is predicted to become the second leading cause of cancer-related deaths by 2030. However, recent developments in staging and treatment provide options to improve the long-term survival rate for an otherwise devastating diagnosis.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 21 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 19 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.
The Center for Healthcare Research & Transformation (CHRT) based at the University of Michigan today released its Prematurity Issue Brief that shows pre-term births -- births at less than 37 weeks of gestation -- are the leading cause of health problems in infants and estimated to cost the U.S. more than $26 billion annually. In addition, the report shows that a black infant in Michigan is 70% more likely to be born prematurely than an infant of any other race.
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
Pancreatic cancer is predicted to become the second leading cause of cancer-related deaths by 2030. However, recent developments in staging and treatment provide options to improve the long-term survival rate for an otherwise devastating diagnosis.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular peritoneal dialysis at the center | 41 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 322 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 91 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.
The Center for Healthcare Research & Transformation (CHRT) based at the University of Michigan today released its Prematurity Issue Brief that shows pre-term births -- births at less than 37 weeks of gestation -- are the leading cause of health problems in infants and estimated to cost the U.S. more than $26 billion annually. In addition, the report shows that a black infant in Michigan is 70% more likely to be born prematurely than an infant of any other race.
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
Pancreatic cancer is predicted to become the second leading cause of cancer-related deaths by 2030. However, recent developments in staging and treatment provide options to improve the long-term survival rate for an otherwise devastating diagnosis.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Us Renal Care Uptown Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 41 |
| Hypercalcemia patient months | 322 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 4 |
| Patients with Serumphosphor | 41 |
| Patients with Serumphosphor less than 3.5 mg/dL | 3 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 21 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 32 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 32 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.
The Center for Healthcare Research & Transformation (CHRT) based at the University of Michigan today released its Prematurity Issue Brief that shows pre-term births -- births at less than 37 weeks of gestation -- are the leading cause of health problems in infants and estimated to cost the U.S. more than $26 billion annually. In addition, the report shows that a black infant in Michigan is 70% more likely to be born prematurely than an infant of any other race.
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
Pancreatic cancer is predicted to become the second leading cause of cancer-related deaths by 2030. However, recent developments in staging and treatment provide options to improve the long-term survival rate for an otherwise devastating diagnosis.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 5 |
| Patient months included in arterial venous fistula and catheter summaries | 5 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.
The Center for Healthcare Research & Transformation (CHRT) based at the University of Michigan today released its Prematurity Issue Brief that shows pre-term births -- births at less than 37 weeks of gestation -- are the leading cause of health problems in infants and estimated to cost the U.S. more than $26 billion annually. In addition, the report shows that a black infant in Michigan is 70% more likely to be born prematurely than an infant of any other race.
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
Pancreatic cancer is predicted to become the second leading cause of cancer-related deaths by 2030. However, recent developments in staging and treatment provide options to improve the long-term survival rate for an otherwise devastating diagnosis.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 35 |
| Hospitalization Rate in facility | 103 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 299 |
| Hospitalization Rate: Lower Confidence Limit | 38.6 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.
The Center for Healthcare Research & Transformation (CHRT) based at the University of Michigan today released its Prematurity Issue Brief that shows pre-term births -- births at less than 37 weeks of gestation -- are the leading cause of health problems in infants and estimated to cost the U.S. more than $26 billion annually. In addition, the report shows that a black infant in Michigan is 70% more likely to be born prematurely than an infant of any other race.
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
Pancreatic cancer is predicted to become the second leading cause of cancer-related deaths by 2030. However, recent developments in staging and treatment provide options to improve the long-term survival rate for an otherwise devastating diagnosis.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Us Renal Care Uptown Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 21.8 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 63.6 |
| Readmission Rate: Lower Confidence Limit | 3.1 |
News Archive
Somaxon Pharmaceuticals, Inc. today announced that it is offering to sell up to 4,000,000 shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. is acting as sole book-running manager in the offering. The co-manager in the offering is Oppenheimer & Co. Inc. Somaxon expects to grant the underwriters an option to purchase up to an additional 600,000 shares of common stock to cover overallotments of shares, if any.
The Center for Healthcare Research & Transformation (CHRT) based at the University of Michigan today released its Prematurity Issue Brief that shows pre-term births -- births at less than 37 weeks of gestation -- are the leading cause of health problems in infants and estimated to cost the U.S. more than $26 billion annually. In addition, the report shows that a black infant in Michigan is 70% more likely to be born prematurely than an infant of any other race.
As e-cigarette use by young people reaches epidemic proportions, researchers at The University of Texas Health Science Center at Houston have received a $3.1 million grant from the National Institutes of Health to conduct the first-ever assessment on the long-term results of a nationwide nicotine vaping prevention program for youth called CATCH My Breath.
Pancreatic cancer is predicted to become the second leading cause of cancer-related deaths by 2030. However, recent developments in staging and treatment provide options to improve the long-term survival rate for an otherwise devastating diagnosis.
› Verified 9 days ago